Kathryn Johnson
Family · New York, NYNPI 1972164291
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.4%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Sobi, Inc accounts for 74.8% of it on its own, with 10 other manufacturers making up the rest. 2025 is the largest year on record at $31,155, more than ten times the $450 reported in 2022. Among family clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 92 payments — averaging $516.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sobi, Inc$36K
- GSK$5K
- CTI Biopharma Corp.$5K
- Karyopharm Therapeutics Inc.$1K
- Pharmaessentia USA Corporation$923
- Novartis$64
- plus $182 from 5 others
What the payments were for
- Consulting fees$6,86014%
- Speaking & faculty fees$26,82256%
- Travel & lodging$11,61224%
- Food & beverage$2,2335%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sobi, Inc | 54 | $35,539 |
| GSK | 11 | $5,042 |
| CTI Biopharma Corp. | 9 | $4,643 |
| Karyopharm Therapeutics Inc. | 7 | $1,134 |
| Pharmaessentia USA Corporation | 1 | $923 |
| Novartis | 3 | $64 |
| Blueprint Medicines Corporation | 2 | $62 |
| Gilead | 2 | $54 |
| Daiichi Sankyo Inc. | 1 | $29 |
| Rigel Pharmaceuticals, Inc. | 1 | $23 |
| Servier Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$47,526 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 25 | $460,895 |
| XareltoRivaroxaban | 14 | $7,738 |
| Hydroxyurea | 15 | $324 |
| Allopurinol | 29 | $169 |
Paid to pharmacies, not to this prescriber.
Other family in New York
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Mary Sullivan-WhalenNew York$137K
- Leslie WoronaNew York$77K
- Thomas SaglimbeniNew York$48K
- Derek PinedaNew York$38K
- Rebecca SchoriNew York$32K
- Evangelia NezisNew York$22K
- Colette NelsonNew York$21K
- Margaret CuomoNew York$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.